AccuRna, Inc. (headquartered in Hongo, Bunkyo-ku, Japan, CEO: Keiko Hattori, hereinafter AccuRna) today announced it has raised an around JPY 520 million financing, in which several investing and business companies participated.
With this funding announced today, AccuRna will further advance its business operation to collaborate with domestic and overseas pharmaceutical companies who are pioneering nucleic acid medicines and will enhance its clinical development activities for new medicines together with several academic organizations.
The companies listed below participated in this funding:
AccuRna has distinctive technologies on DDS (Drug Delivery System) for nucleic acid medicines.
Nucleic acid medicines are next-generation pharmaceuticals which utilize nucleic acids, such as RNA and DNA. There are a substantial number of R&D projects for those new medicines all over the world because they enable molecule targeting which have not been realized by conventional medicines, such as small molecules and antibody drugs. Nucleic acid medicines, however, have technical challenges including their stability in the body and effective delivery to the therapeutic targets.
AccuRna’s DDS technologies provide solutions for those challenges of nucleic acid medicines.
Up to now, AccuRna has conducted collaborative research with several domestic and overseas pharmaceutical companies using its own DDS technologies and carried out new drug development with academic organizations, such as universities, which have been developing new nucleic acid medicines. And in anticipation of this fundraising, AccuRna has enhanced its own organization for the operation and R&D.
With this funding announced today, AccuRna will improve its business operation to further strengthen its partnership with domestic and overseas pharmaceutical companies for widespread use of its DDS technologies, and boost some translational research projects in academia one of which will enter a clinical trial for a new medicine development.
Business Research and development of nucleic acid-based drugs using DDS technologies
Founded in December 2015
Headquartered in Sanyu Bld. 201, 3-42-1, Hongo, Bunkyo-ku, Tokyo, Japan
CEO Keiko Hattori
Sanyu Bld.201, 3-42-1, Hongo, Bunkyo-ku, Tokyo